- Home
- PLX vs TZOO Comparison
PLX vs TZOO Comparison
Compare PLX & TZOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- TZOO
- Stock Information
- Founded
- PLX 1993
- TZOO 1998
- Country
- PLX United States
- TZOO United States
- Employees
- PLX N/A
- TZOO N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- TZOO Advertising
- Sector
- PLX Health Care
- TZOO Consumer Discretionary
- Exchange
- PLX Nasdaq
- TZOO Nasdaq
- Market Cap
- PLX 160.2M
- TZOO 144.5M
- IPO Year
- PLX 1998
- TZOO 2002
- Fundamental
- Price
- PLX $1.55
- TZOO $13.22
- Analyst Decision
- PLX Strong Buy
- TZOO Strong Buy
- Analyst Count
- PLX 1
- TZOO 4
- Target Price
- PLX $15.00
- TZOO $23.50
- AVG Volume (30 Days)
- PLX 1.4M
- TZOO 85.5K
- Earning Date
- PLX 05-09-2025
- TZOO 07-24-2025
- Dividend Yield
- PLX N/A
- TZOO N/A
- EPS Growth
- PLX N/A
- TZOO 11.63
- EPS
- PLX 0.05
- TZOO 1.01
- Revenue
- PLX $59,764,000.00
- TZOO $85,057,000.00
- Revenue This Year
- PLX $65.02
- TZOO $16.82
- Revenue Next Year
- PLX $57.34
- TZOO $25.91
- P/E Ratio
- PLX $32.18
- TZOO $13.76
- Revenue Growth
- PLX 0.18
- TZOO 0.23
- 52 Week Low
- PLX $0.82
- TZOO $7.12
- 52 Week High
- PLX $3.10
- TZOO $24.85
- Technical
- Relative Strength Index (RSI)
- PLX 30.32
- TZOO 46.90
- Support Level
- PLX $1.52
- TZOO $12.86
- Resistance Level
- PLX $1.79
- TZOO $14.18
- Average True Range (ATR)
- PLX 0.09
- TZOO 0.53
- MACD
- PLX -0.01
- TZOO -0.04
- Stochastic Oscillator
- PLX 26.44
- TZOO 17.82
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About TZOO Travelzoo
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment, which is the key revenue driver, consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; and New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties.